Calciphylaxis Treatment Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The calciphylaxis treatment market size has grown rapidly in recent years. It will grow from $1.86 billion in 2024 to $2.05 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to increasing incidence of calciphylaxis, rising awareness among healthcare professionals, expanding healthcare infrastructure, clinical research and drug development.

The calciphylaxis treatment market size is expected to see strong growth in the next few years. It will grow to $2.84 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to rising healthcare expenditure, increasing collaboration and partnerships, focus on personalized medicine, regulatory support and expedited approvals, patient-centric healthcare approaches. Major trends in the forecast period include emerging therapeutic modalities, diagnostic advancements, increased research and development, collaborative initiatives, patient-centric approaches, regulatory landscape dynamics.

The anticipated rise in the prevalence of kidney diseases is set to drive the growth of the calciphylaxis treatment market. Kidney diseases, affecting the vital function of filtering waste products and excess fluids, disrupt calcium and phosphate metabolism, increasing the risk of calciphylaxis. With an estimated 7.19 million people affected by chronic kidney disease in the UK in 2023, representing over 10% of the population and expected to reach 7.61 million by 2033, the growing prevalence of kidney diseases will be a key driver for the calciphylaxis treatment market.

The expansion of ongoing clinical trials is expected to further boost the calciphylaxis treatment market. Clinical trials play a pivotal role in assessing the safety and efficacy of potential treatments, contributing valuable evidence for improved therapeutic approaches. With the number of registered studies increasing from 437,523 in 2022 to 468,457 in 2023 globally, the ongoing clinical trials provide essential insights and advancements in the medical understanding and treatment of calciphylaxis, contributing to the market's growth.

Leading companies in the calciphylaxis treatment market are focusing on developing advanced diagnostic techniques and health evaluation services to enhance profitability. By introducing comprehensive in-home kidney health evaluations, companies such as Signify Health, Inc. aim to provide convenient and proactive monitoring solutions for kidney health. Such initiatives, including urinalysis and estimated glomerular filtration rate assessments, prove valuable in early detection and management of chronic kidney health issues, including conditions such as calciphylaxis.

In January 2024, Merck KGaA, a Germany-based science and technology company providing calciphylaxis treatment, partnered with Inspirna Inc. Through this partnership, Merck KGaA expanded its colorectal cancer portfolio via a licensing agreement for the drug ompenaclid (RGX-202). This first-in-class oral inhibitor targets the creatine transport channel SLC6A8 and is currently in Phase II development for advanced RAS-mutated colorectal cancer (mCRC). Inspirna Inc. is a U.S.-based clinical-stage biopharmaceutical company.

Major companies operating in the calciphylaxis treatment market report are Pfizer Inc., Merck And Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi SA, 3M Company, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Novo Nordisk, Viatris (Mylan N.V.), Regeneron Pharmaceuticals Inc., Smith And Nephew Plc., Incyte Corporation, ConvaTec Inc., Vifor Pharma Group, BSN Medical GmbH, Panion And BF Biotech Inc., Inozyme Pharma Inc., Sanifit Therapeutics S.A, Hope Pharmaceuticals, Menlo Therapeutics.

North America was the largest region in the calciphylaxis treatment market in 2024 Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calciphylaxis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the calciphylaxis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The calciphylaxis treatment market consists of revenues earned by entities by providing diagnostic services such as infrared thermography, electrolyte and mineral analysis, and measuring serum parathyroid hormone (PTH) levels to diagnose and assess the severity of calciphylaxis in patients. The market value includes the value of related goods sold by the service provider or included within the service offering. The calciphylaxis treatment market also includes sales of intensive wound care, clot-dissolving therapy, and vitamin K therapy, which are comprehensive treatment approaches for managing calciphylaxis. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Calciphylaxis, also known as calcific uremic arteriolopathy (CUA), is a rare and severe medical condition characterized by the deposition of calcium in small blood vessels and tissues. It primarily affects individuals with kidney disease, especially those with end-stage renal disease (ESRD). The treatment approach involves pain management and nutritional support therapies to address symptoms such as painful and non-healing skin ulcers, tissue necrosis, and potential complications such as sepsis, which can pose life-threatening risks.

The main types of calciphylaxis treatment include medication, hyperbaric oxygen therapy, and other interventions. Medication involves the use of pharmaceutical drugs to manage symptoms and underlying causes. Medications such as sodium thiosulfate, opioids, or non-opioid drugs may be employed to treat or prevent infections, manage pain, and address aspects associated with calciphylaxis. Diagnosis is typically carried out through imaging, blood tests, and deep skin biopsies performed by end users such as hospitals, clinics, medical research centers, and academic institutes.

The calciphylaxis treatment market research report is one of a series of new reports that provides calciphylaxis treatment market statistics, including calciphylaxis treatment industry global market size, regional shares, competitors with an calciphylaxis treatment market share, detailed calciphylaxis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the calciphylaxis treatment industry. This calciphylaxis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.